Ionis Pharmaceuticals, Inc. (IONS)
USD 27.15
(-4.8%)
USD 27.15
(-4.8%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.99 Billion USD | 18.0% |
| 2022 | 2.53 Billion USD | -2.99% |
| 2021 | 2.61 Billion USD | 9.29% |
| 2020 | 2.39 Billion USD | -26.07% |
| 2019 | 3.23 Billion USD | 21.19% |
| 2018 | 2.66 Billion USD | 101.8% |
| 2017 | 1.32 Billion USD | 44.88% |
| 2016 | 912.46 Million USD | -4.56% |
| 2015 | 956.1 Million USD | 0.03% |
| 2014 | 955.8 Million USD | 12.83% |
| 2013 | 847.15 Million USD | 55.25% |
| 2012 | 545.68 Million USD | 12.54% |
| 2011 | 484.89 Million USD | -11.91% |
| 2010 | 550.47 Million USD | -16.24% |
| 2009 | 657.18 Million USD | 14.46% |
| 2008 | 574.15 Million USD | 121.8% |
| 2007 | 258.85 Million USD | 1.15% |
| 2006 | 255.9 Million USD | 53.82% |
| 2005 | 166.37 Million USD | -20.18% |
| 2004 | 208.42 Million USD | -37.77% |
| 2003 | 334.94 Million USD | -23.65% |
| 2002 | 438.68 Million USD | 5.18% |
| 2001 | 417.06 Million USD | 127.58% |
| 2000 | 183.25 Million USD | 77.75% |
| 1999 | 103.1 Million USD | 7.28% |
| 1998 | 96.1 Million USD | -18.49% |
| 1997 | 117.9 Million USD | 16.39% |
| 1996 | 101.3 Million USD | 1.71% |
| 1995 | 99.6 Million USD | 49.55% |
| 1994 | 66.6 Million USD | -15.48% |
| 1993 | 78.8 Million USD | 41.98% |
| 1992 | 55.5 Million USD | -24.59% |
| 1991 | 73.6 Million USD | 1611.63% |
| 1990 | 4.3 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 2.69 Billion USD | -2.63% |
| 2024 Q1 | 2.76 Billion USD | -7.56% |
| 2023 Q3 | 2.93 Billion USD | -1.25% |
| 2023 Q2 | 2.97 Billion USD | 2.98% |
| 2023 Q1 | 2.88 Billion USD | 13.85% |
| 2023 FY | 2.99 Billion USD | 18.0% |
| 2023 Q4 | 2.99 Billion USD | 1.91% |
| 2022 Q4 | 2.53 Billion USD | 4.63% |
| 2022 Q3 | 2.42 Billion USD | -1.39% |
| 2022 Q1 | 2.51 Billion USD | -3.56% |
| 2022 FY | 2.53 Billion USD | -2.99% |
| 2022 Q2 | 2.45 Billion USD | -2.5% |
| 2021 FY | 2.61 Billion USD | 9.29% |
| 2021 Q2 | 2.49 Billion USD | 11.05% |
| 2021 Q1 | 2.24 Billion USD | -5.92% |
| 2021 Q4 | 2.61 Billion USD | 8.16% |
| 2021 Q3 | 2.41 Billion USD | -3.29% |
| 2020 FY | 2.39 Billion USD | -26.07% |
| 2020 Q4 | 2.39 Billion USD | -22.8% |
| 2020 Q2 | 3.07 Billion USD | -0.39% |
| 2020 Q1 | 3.09 Billion USD | -4.39% |
| 2020 Q3 | 3.09 Billion USD | 0.54% |
| 2019 Q4 | 3.23 Billion USD | 11.68% |
| 2019 Q1 | 2.83 Billion USD | 6.3% |
| 2019 Q2 | 2.87 Billion USD | 1.48% |
| 2019 FY | 3.23 Billion USD | 21.19% |
| 2019 Q3 | 2.89 Billion USD | 0.59% |
| 2018 Q4 | 2.66 Billion USD | 18.68% |
| 2018 Q3 | 2.24 Billion USD | 0.03% |
| 2018 Q1 | 1.29 Billion USD | -1.7% |
| 2018 FY | 2.66 Billion USD | 101.8% |
| 2018 Q2 | 2.24 Billion USD | 72.93% |
| 2017 Q4 | 1.32 Billion USD | 5.55% |
| 2017 Q1 | 1.08 Billion USD | 18.8% |
| 2017 FY | 1.32 Billion USD | 44.88% |
| 2017 Q3 | 1.25 Billion USD | 14.83% |
| 2017 Q2 | 1.09 Billion USD | 0.63% |
| 2016 FY | 912.46 Million USD | -4.56% |
| 2016 Q1 | 875.81 Million USD | -8.4% |
| 2016 Q2 | 811.1 Million USD | -7.39% |
| 2016 Q3 | 843.58 Million USD | 4.0% |
| 2016 Q4 | 912.46 Million USD | 8.17% |
| 2015 Q3 | 988 Million USD | 1.2% |
| 2015 Q1 | 955.43 Million USD | -0.04% |
| 2015 Q4 | 956.1 Million USD | -3.23% |
| 2015 Q2 | 976.25 Million USD | 2.18% |
| 2015 FY | 956.1 Million USD | 0.03% |
| 2014 Q3 | 793.8 Million USD | -2.93% |
| 2014 Q4 | 955.8 Million USD | 20.41% |
| 2014 FY | 955.8 Million USD | 12.83% |
| 2014 Q2 | 817.77 Million USD | -2.02% |
| 2014 Q1 | 834.61 Million USD | -1.48% |
| 2013 Q3 | 881.91 Million USD | 11.83% |
| 2013 Q4 | 847.15 Million USD | -3.94% |
| 2013 Q1 | 552.96 Million USD | 1.33% |
| 2013 FY | 847.15 Million USD | 55.25% |
| 2013 Q2 | 788.65 Million USD | 42.62% |
| 2012 Q3 | 485.68 Million USD | 2.81% |
| 2012 FY | 545.68 Million USD | 12.54% |
| 2012 Q4 | 545.68 Million USD | 12.35% |
| 2012 Q1 | 470.8 Million USD | -2.91% |
| 2012 Q2 | 472.39 Million USD | 0.34% |
| 2011 Q3 | 505.78 Million USD | -4.49% |
| 2011 Q2 | 529.57 Million USD | 4.67% |
| 2011 Q1 | 505.94 Million USD | -8.09% |
| 2011 FY | 484.89 Million USD | -11.91% |
| 2011 Q4 | 484.89 Million USD | -4.13% |
| 2010 Q1 | 599.72 Million USD | -8.74% |
| 2010 FY | 550.47 Million USD | -16.24% |
| 2010 Q4 | 550.47 Million USD | -4.41% |
| 2010 Q2 | 606.35 Million USD | 1.11% |
| 2010 Q3 | 575.85 Million USD | -5.03% |
| 2009 FY | 657.18 Million USD | 14.46% |
| 2009 Q2 | 709.16 Million USD | -2.12% |
| 2009 Q3 | 680.57 Million USD | -4.03% |
| 2009 Q4 | 657.18 Million USD | -3.44% |
| 2009 Q1 | 724.5 Million USD | 26.19% |
| 2008 Q1 | 405.42 Million USD | 56.62% |
| 2008 Q4 | 574.15 Million USD | -1.8% |
| 2008 Q3 | 584.69 Million USD | -4.05% |
| 2008 Q2 | 609.39 Million USD | 50.31% |
| 2008 FY | 574.15 Million USD | 121.8% |
| 2007 FY | 258.85 Million USD | 1.15% |
| 2007 Q1 | 349.9 Million USD | 36.73% |
| 2007 Q2 | 263.25 Million USD | -24.76% |
| 2007 Q3 | 213 Million USD | -19.09% |
| 2007 Q4 | 258.85 Million USD | 21.53% |
| 2006 Q2 | 201.91 Million USD | 34.04% |
| 2006 FY | 255.9 Million USD | 53.82% |
| 2006 Q4 | 255.9 Million USD | 36.29% |
| 2006 Q3 | 187.76 Million USD | -7.01% |
| 2006 Q1 | 150.63 Million USD | -9.46% |
| 2005 Q1 | 175.64 Million USD | -15.73% |
| 2005 Q3 | 177.38 Million USD | 21.06% |
| 2005 Q4 | 166.37 Million USD | -6.21% |
| 2005 Q2 | 146.52 Million USD | -16.58% |
| 2005 FY | 166.37 Million USD | -20.18% |
| 2004 Q3 | 255.27 Million USD | -8.82% |
| 2004 Q4 | 208.42 Million USD | -18.35% |
| 2004 Q1 | 312.72 Million USD | -6.63% |
| 2004 FY | 208.42 Million USD | -37.77% |
| 2004 Q2 | 279.96 Million USD | -10.48% |
| 2003 Q4 | 334.94 Million USD | -5.26% |
| 2003 FY | 334.94 Million USD | -23.65% |
| 2003 Q3 | 353.54 Million USD | -4.67% |
| 2003 Q2 | 370.85 Million USD | -10.66% |
| 2003 Q1 | 415.09 Million USD | -5.38% |
| 2002 Q2 | 443.22 Million USD | 10.9% |
| 2002 Q4 | 438.68 Million USD | 3.34% |
| 2002 FY | 438.68 Million USD | 5.18% |
| 2002 Q1 | 399.66 Million USD | -4.17% |
| 2002 Q3 | 424.52 Million USD | -4.22% |
| 2001 Q4 | 417.06 Million USD | 41.66% |
| 2001 FY | 417.06 Million USD | 127.58% |
| 2001 Q3 | 294.41 Million USD | 57.0% |
| 2001 Q2 | 187.52 Million USD | 14.79% |
| 2001 Q1 | 163.36 Million USD | -10.85% |
| 2000 Q1 | 151.84 Million USD | 47.28% |
| 2000 FY | 183.25 Million USD | 77.75% |
| 2000 Q2 | 177.02 Million USD | 16.58% |
| 2000 Q3 | 176.57 Million USD | -0.25% |
| 2000 Q4 | 183.25 Million USD | 3.78% |
| 1999 Q3 | 94.1 Million USD | -1.26% |
| 1999 Q2 | 95.3 Million USD | 14.96% |
| 1999 Q4 | 103.1 Million USD | 9.56% |
| 1999 Q1 | 82.9 Million USD | -13.74% |
| 1999 FY | 103.1 Million USD | 7.28% |
| 1998 Q1 | 101.3 Million USD | -14.08% |
| 1998 Q4 | 96.1 Million USD | -10.02% |
| 1998 Q3 | 106.8 Million USD | -9.18% |
| 1998 FY | 96.1 Million USD | -18.49% |
| 1998 Q2 | 117.6 Million USD | 16.09% |
| 1997 Q1 | 97.8 Million USD | -3.46% |
| 1997 Q3 | 97.3 Million USD | -1.82% |
| 1997 FY | 117.9 Million USD | 16.39% |
| 1997 Q4 | 117.9 Million USD | 21.17% |
| 1997 Q2 | 99.1 Million USD | 1.33% |
| 1996 Q3 | 84.9 Million USD | -7.31% |
| 1996 Q2 | 91.6 Million USD | -7.19% |
| 1996 FY | 101.3 Million USD | 1.71% |
| 1996 Q1 | 98.7 Million USD | -0.9% |
| 1996 Q4 | 101.3 Million USD | 19.32% |
| 1995 Q4 | 99.6 Million USD | 23.73% |
| 1995 Q2 | 58.3 Million USD | -3.16% |
| 1995 Q3 | 80.5 Million USD | 38.08% |
| 1995 Q1 | 60.2 Million USD | -9.61% |
| 1995 FY | 99.6 Million USD | 49.55% |
| 1994 Q1 | 80.3 Million USD | 1.9% |
| 1994 FY | 66.6 Million USD | -15.48% |
| 1994 Q4 | 66.6 Million USD | -6.59% |
| 1994 Q2 | 73.9 Million USD | -7.97% |
| 1994 Q3 | 71.3 Million USD | -3.52% |
| 1993 Q2 | 62.4 Million USD | -7.14% |
| 1993 FY | 78.8 Million USD | 41.98% |
| 1993 Q3 | 60.4 Million USD | -3.21% |
| 1993 Q4 | 78.8 Million USD | 30.46% |
| 1993 Q1 | 67.2 Million USD | 21.08% |
| 1992 Q2 | 65 Million USD | -5.11% |
| 1992 FY | 55.5 Million USD | -24.59% |
| 1992 Q1 | 68.5 Million USD | -6.93% |
| 1992 Q3 | 60.7 Million USD | -6.62% |
| 1992 Q4 | 55.5 Million USD | -8.57% |
| 1991 FY | 73.6 Million USD | 1611.63% |
| 1991 Q3 | 40.4 Million USD | -7.34% |
| 1991 Q4 | 73.6 Million USD | 82.18% |
| 1991 Q1 | 19 Million USD | 341.86% |
| 1991 Q2 | 43.6 Million USD | 129.47% |
| 1990 Q4 | 4.3 Million USD | 0.0% |
| 1990 FY | 4.3 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | -100.933% |
| Alkermes plc | 2.13 Billion USD | -39.97% |
| Agenus Inc. | 313.91 Million USD | -852.516% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 21.928% |
| Aptorum Group Limited | 20.64 Million USD | -14386.719% |
| Ardelyx, Inc. | 297.57 Million USD | -904.799% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -290.577% |
| Bicycle Therapeutics plc | 595.34 Million USD | -402.243% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -3956.975% |
| ChromaDex Corporation | 54.96 Million USD | -5340.055% |
| Chimerix, Inc. | 212.77 Million USD | -1305.281% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -10475.942% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -578.07% |
| CRISPR Therapeutics AG | 2.22 Billion USD | -34.11% |
| Precision BioSciences, Inc. | 159.78 Million USD | -1771.356% |
| Dyadic International, Inc. | 8.21 Million USD | -36278.953% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -9320.517% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1684.841% |
| Lantern Pharma Inc. | 43.64 Million USD | -6750.482% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -1753.308% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -20511.738% |
| Incyte Corporation | 6.78 Billion USD | 55.912% |
| IO Biotech, Inc. | 150.71 Million USD | -1883.885% |
| Jaguar Health, Inc. | 50.76 Million USD | -5790.259% |
| Novavax, Inc. | 1.85 Billion USD | -61.16% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -686.019% |
| Opthea Limited | 188.79 Million USD | -1483.798% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | -258.925% |
| ContextLogic Inc. | 423 Million USD | -606.873% |
| MiMedx Group, Inc. | 239.04 Million USD | -1150.83% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -1621.142% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -57738.393% |
| NextCure, Inc. | 129.41 Million USD | -2210.399% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -5442.508% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -8040.902% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -9156.902% |
| Vaxcyte, Inc. | 1.4 Billion USD | -112.376% |
| PDS Biotechnology Corporation | 59.39 Million USD | -4934.632% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -366.8% |
| Pharming Group N.V. | 462.85 Million USD | -546.008% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -7630.279% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -375.706% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -15700.694% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -15700.694% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1708.657% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -6502.495% |
| Acelyrin, Inc. | 742.69 Million USD | -302.6% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -45296.82% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -46597.985% |
| Summit Therapeutics Inc. | 202.94 Million USD | -1373.312% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -3920.319% |
| Senti Biosciences, Inc. | 119.48 Million USD | -2402.487% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -1209.471% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -1677.963% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -36086.276% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -62535.47% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -537.281% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -2318.115% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -987.501% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -532.364% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -29490.025% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -1293.934% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -264003.54% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -622.515% |
| Immix Biopharma, Inc. | 19.92 Million USD | -14906.514% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -708.073% |
| MEI Pharma, Inc. | 41.37 Million USD | -7126.76% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -9126.909% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -777.374% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -2450.712% |
| Fortress Biotech, Inc. | 167.52 Million USD | -1684.841% |
| Precigen, Inc. | 151.04 Million USD | -1879.616% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -8689.676% |
| AlloVir, Inc. | 190.79 Million USD | -1467.157% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -694.279% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -490.67% |
| ImmuCell Corporation | 43.8 Million USD | -6725.386% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -360.496% |
| Onconetix, Inc. | 88.82 Million USD | -3266.385% |
| PureTech Health plc | 693.97 Million USD | -330.863% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -2960.933% |
| Elevation Oncology, Inc. | 89.09 Million USD | -3256.2% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -48111.416% |
| Seer, Inc. | 436.26 Million USD | -585.373% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -3564.439% |
| Innoviva, Inc. | 1.24 Billion USD | -140.455% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -2157.97% |
| ESSA Pharma Inc. | 149.12 Million USD | -1905.116% |
| GlycoMimetics, Inc. | 45.31 Million USD | -6498.201% |
| GT Biopharma, Inc. | 14.1 Million USD | -21092.657% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -871.14% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -1137.085% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -533.615% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -5797.927% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -3040.436% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -473321.281% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -427.963% |
| Aptose Biosciences Inc. | 12.92 Million USD | -23038.416% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -13420.998% |
| Soligenix, Inc. | 9.79 Million USD | -30419.266% |
| Century Therapeutics, Inc. | 360.69 Million USD | -728.984% |
| Kura Oncology, Inc. | 448.93 Million USD | -566.037% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -998.689% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -17188.65% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -2595.912% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -1357.498% |
| Autolus Therapeutics plc | 375.38 Million USD | -696.543% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -1088.253% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -741.837% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -5985.793% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -352.264% |
| GRI Bio, Inc. | 2.95 Million USD | -101052.639% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -28094.326% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -1653.554% |
| IGM Biosciences, Inc. | 423.41 Million USD | -606.187% |
| INmune Bio, Inc. | 57 Million USD | -5145.648% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1243.816% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3462.101% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -11348.82% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -43340.176% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -3874.785% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -1930.499% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1706.646% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -374.913% |
| Verastem, Inc. | 149.71 Million USD | -1897.136% |
| Abeona Therapeutics Inc. | 64 Million USD | -4571.842% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -483.823% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -1835.86% |
| Histogen Inc. | 19.07 Million USD | -15576.988% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -13101.099% |
| Surrozen, Inc. | 46.08 Million USD | -6388.872% |
| Organovo Holdings, Inc. | 6.34 Million USD | -46995.165% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -69297.44% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -1976.053% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -25235.299% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -3872.567% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -34997.831% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -723.782% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -16424.85% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -596.334% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -23608.677% |
| Apollomics, Inc. | 55.38 Million USD | -5298.509% |
| Amarin Corporation plc | 831.68 Million USD | -259.52% |
| Mesoblast Limited | 669.15 Million USD | -346.844% |
| Turnstone Biologics Corp. | 112.81 Million USD | -2550.421% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -419.327% |
| Synaptogenix, Inc. | 31.11 Million USD | -9510.156% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -24440.972% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -445.572% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -50818.581% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -40608.064% |
| Exelixis, Inc. | 2.94 Billion USD | -1.622% |
| Better Therapeutics, Inc. | 22.94 Million USD | -12932.611% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -720.234% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -279.1% |
| NLS Pharmaceutics AG | 1.84 Million USD | -161819.507% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -37375.989% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -20247.547% |
| Gritstone bio, Inc. | 177.76 Million USD | -1581.999% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -3034.905% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -16639.597% |
| Avid Bioservices, Inc. | 336.55 Million USD | -788.43% |
| Insmed Incorporated | 1.32 Billion USD | -124.845% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -30954.891% |
| MediWound Ltd. | 66.45 Million USD | -4399.123% |
| OmniAb, Inc. | 401.98 Million USD | -643.827% |
| Alector, Inc. | 621.82 Million USD | -380.853% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -733.818% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -55498.215% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -5174.24% |
| Zai Lab Limited | 1.03 Billion USD | -188.535% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -524.945% |
| Aura Biosciences, Inc. | 255.07 Million USD | -1072.232% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -298.661% |
| Immunic, Inc. | 54.29 Million USD | -5406.68% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -1023.141% |
| Veracyte, Inc. | 1.13 Billion USD | -162.789% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -25190.765% |
| FibroGen, Inc. | 423.52 Million USD | -605.99% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -85014.489% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -63026.902% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -54971.077% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 73.756% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -33858.796% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -477.843% |
| TG Therapeutics, Inc. | 329.58 Million USD | -807.218% |
| Galecto, Inc. | 38.22 Million USD | -7721.885% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -10327.089% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 31.376% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -1170.187% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -11936.358% |
| XBiotech Inc. | 227.24 Million USD | -1215.804% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -3034.905% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -1996.825% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -945.787% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -2238.387% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -682.743% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | -100.54% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -719.553% |
| Vaxxinity, Inc. | 44.35 Million USD | -6641.533% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -478.395% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -15967.595% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -880.191% |
| NexImmune, Inc. | 8.59 Million USD | -34692.759% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -27804.983% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -17357.837% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 90.961% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -13398.507% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -762158.167% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -1625.085% |
| Ainos, Inc. | 31.84 Million USD | -9290.398% |
| Pluri Inc. | 39.52 Million USD | -7464.632% |
| Prothena Corporation plc | 696.38 Million USD | -329.372% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -957.998% |
| Celularity Inc. | 143.88 Million USD | -1978.041% |
| Rallybio Corporation | 115.62 Million USD | -2486.12% |
| Cue Biopharma, Inc. | 61.53 Million USD | -4759.535% |
| MeiraGTx Holdings plc | 458.16 Million USD | -552.615% |
| Omeros Corporation | 378.26 Million USD | -690.462% |
| Humacyte, Inc. | 128.22 Million USD | -2231.931% |
| Immunocore Holdings plc | 597 Million USD | -400.849% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -9465.476% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -4263.158% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -184.972% |
| CalciMedica, Inc. | 12.18 Million USD | -24438.958% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -1078.818% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -1649.521% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -861.33% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -428.936% |
| Pulmatrix, Inc. | 33.95 Million USD | -8705.206% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -10914.779% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -2022.756% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -129.833% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -2196.716% |
| Cytokinetics, Incorporated | 824.31 Million USD | -262.734% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -14055.527% |
| Nutriband Inc. | 7.51 Million USD | -39676.65% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -3687.106% |
| Vor Biopharma Inc. | 209.82 Million USD | -1325.011% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 58.6% |
| Evogene Ltd. | 51.1 Million USD | -5751.298% |
| ProKidney Corp. | 420.55 Million USD | -610.987% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -5353.052% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -31307.402% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -447.251% |
| CorMedix Inc. | 82.05 Million USD | -3543.765% |
| BioLineRx Ltd. | 63.92 Million USD | -4577.469% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -642.751% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -10503.092% |
| Atai Life Sciences N.V. | 293.47 Million USD | -918.84% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -1732.944% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -2246.664% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -432.016% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -2991.504% |
| MediciNova, Inc. | 66.26 Million USD | -4411.956% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -3299.818% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -66906.442% |
| GeoVax Labs, Inc. | 9.28 Million USD | -32109.431% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -408.312% |
| Biomea Fusion, Inc. | 199.92 Million USD | -1395.582% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | -57.109% |
| Mereo BioPharma Group plc | 66.49 Million USD | -4396.416% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -516.388% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -387.872% |
| Absci Corporation | 234.48 Million USD | -1175.193% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -40775.899% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -779.715% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -1711.265% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -468.107% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -976.755% |
| Allakos Inc. | 243.61 Million USD | -1127.401% |
| Imunon, Inc. | 21.91 Million USD | -13542.041% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -1060.319% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -381.093% |
| BioAtla, Inc. | 119.65 Million USD | -2398.848% |
| NLS Pharmaceutics AG | 1.84 Million USD | -161819.507% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -92759.379% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -365.137% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -3016.769% |
| XOMA Corporation | 234.3 Million USD | -1176.167% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -1251.537% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2276.015% |
| aTyr Pharma, Inc. | 122.06 Million USD | -2349.533% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -1842.829% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -415.289% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -509.691% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -2606.707% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -19626.606% |
| Akari Therapeutics, Plc | 4.35 Million USD | -68558.37% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -17450.118% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -72.51% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -96854.785% |
| UroGen Pharma Ltd. | 178.31 Million USD | -1576.886% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -535.191% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -537958.537% |
| Orgenesis Inc. | 14.55 Million USD | -20447.499% |
| Entera Bio Ltd. | 11.76 Million USD | -25314.977% |
| GH Research PLC | 226.3 Million USD | -1221.287% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -5366.91% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -2683.119% |
| Xencor, Inc. | 952.69 Million USD | -213.855% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -38314.183% |
| Replimune Group, Inc. | 487.72 Million USD | -513.069% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -36946.698% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -361.118% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -96854.785% |
| Portage Biotech Inc. | 7.77 Million USD | -38337.743% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -66906.442% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -979.663% |
| OncoCyte Corporation | 74.89 Million USD | -3892.512% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -146958.893% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -51571.962% |
| Purple Biotech Ltd. | 44.3 Million USD | -6649.293% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -8661.859% |
| scPharmaceuticals Inc. | 94.47 Million USD | -3064.801% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -16470.124% |
| HilleVax, Inc. | 344.43 Million USD | -768.112% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -94045.844% |
| Tharimmune, Inc. | 10.94 Million USD | -27215.592% |
| Genprex, Inc. | 10.67 Million USD | -27921.613% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -502.6% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -3006.504% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -123151.113% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -71682.844% |
| OKYO Pharma Limited | 1.54 Million USD | -193901.287% |
| Savara Inc. | 177.56 Million USD | -1583.94% |
| Curis, Inc. | 77.28 Million USD | -3769.041% |
| Daré Bioscience, Inc. | 21.28 Million USD | -13949.628% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -4575.728% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -36878.382% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -15335.816% |
| BeiGene, Ltd. | 5.8 Billion USD | 48.494% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -24471.222% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | -43.162% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -735.33% |
| Erasca, Inc. | 395.29 Million USD | -656.412% |
| bluebird bio, Inc. | 619.16 Million USD | -382.923% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -69060.694% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 56.296% |
| DBV Technologies S.A. | 182.98 Million USD | -1534.044% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -69060.694% |
| Moderna, Inc. | 18.42 Billion USD | 83.773% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -16313.636% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -25707.63% |
| Molecular Templates, Inc. | 35.38 Million USD | -8350.589% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -2062.566% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -279.012% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -884.37% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -2776.563% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -542.16% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -853.963% |
| MacroGenics, Inc. | 306.82 Million USD | -874.536% |
| RenovoRx, Inc. | 1.46 Million USD | -203861.255% |
| Adicet Bio, Inc. | 207.29 Million USD | -1342.424% |
| Prime Medicine, Inc. | 193.85 Million USD | -1442.459% |
| Aditxt, Inc. | 44.57 Million USD | -6607.457% |
| Adagene Inc. | 115.72 Million USD | -2483.688% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -67029.437% |
| Quantum-Si incorporated | 298.25 Million USD | -902.539% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | -101.02% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -38686.15% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -751.191% |
| SciSparc Ltd. | 11.18 Million USD | -26640.047% |
| Vericel Corporation | 353.65 Million USD | -745.472% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -24383.483% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -5154.903% |
| Generation Bio Co. | 374.75 Million USD | -697.867% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -1074.115% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -1785.684% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -775.916% |
| Invivyd, Inc. | 229.18 Million USD | -1204.677% |
| Relay Therapeutics, Inc. | 843.98 Million USD | -254.282% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -24470.614% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -1539.384% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -14539.992% |
| 2seventy bio, Inc. | 565.42 Million USD | -428.818% |
| ADMA Biologics, Inc. | 329.18 Million USD | -808.334% |
| Clene Inc. | 52.34 Million USD | -5612.676% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -4990.842% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -2201.932% |
| GeoVax Labs, Inc. | 9.28 Million USD | -32109.431% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -357.408% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -2785.859% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -2193.246% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -2965.104% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -4111.547% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -1132.75% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | -52.548% |
| Evaxion Biotech A/S | 12.88 Million USD | -23099.32% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -1086.254% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -297.253% |
| Trevena, Inc. | 40.6 Million USD | -7263.802% |
| Surrozen, Inc. | 46.08 Million USD | -6388.872% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -1223.878% |
| Cingulate Inc. | 3.49 Million USD | -85540.178% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -17881.069% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -4451.792% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -25489.794% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -1013.55% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -299.232% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -2275.109% |
| Clearmind Medicine Inc. | 4.32 Million USD | -69044.381% |
| Kronos Bio, Inc. | 213.27 Million USD | -1301.953% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -1771.321% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -34828.259% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -711.439% |
| Statera Biopharma, Inc. | 21.16 Million USD | -14024.31% |
| ImmunityBio, Inc. | 504.45 Million USD | -492.737% |
| Korro Bio, Inc. | 221.66 Million USD | -1248.927% |
| Kineta, Inc. | 10.28 Million USD | -28983.474% |
| BioVie Inc. | 25.2 Million USD | -11761.437% |
| Codexis, Inc. | 136.56 Million USD | -2089.55% |
| Celularity Inc. | 143.88 Million USD | -1978.041% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -370.616% |
| Celcuity Inc. | 191.21 Million USD | -1463.687% |
| Virax Biolabs Group Limited | 5.48 Million USD | -54423.868% |
| Cibus, Inc. | 544.41 Million USD | -449.231% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -2275.071% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -14454.478% |
| IN8bio, Inc. | 33.7 Million USD | -8770.248% |
| Kodiak Sciences Inc. | 479.37 Million USD | -523.748% |
| Annexon, Inc. | 297.67 Million USD | -904.479% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -1628.265% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -2075.088% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -14143.186% |
| Eyenovia, Inc. | 28.77 Million USD | -10289.635% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -1197.054% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -41290.808% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -4807.711% |
| Arcellx, Inc. | 825.13 Million USD | -262.375% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -3562.643% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -546.817% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -9623.811% |
| Moolec Science SA | 24.05 Million USD | -12332.065% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -864.151% |
| Geron Corporation | 394.07 Million USD | -658.755% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -2839.801% |
| Royalty Pharma plc | 16.38 Billion USD | 81.748% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -402.56% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -42646.978% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -24760.675% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -1222.69% |
| Humacyte, Inc. | 128.22 Million USD | -2231.931% |
| Structure Therapeutics Inc. | 482.01 Million USD | -520.325% |
| 89bio, Inc. | 596.26 Million USD | -401.464% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -1085.821% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -161525.514% |
| Genelux Corporation | 27.89 Million USD | -10619.793% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -3244.487% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -1203.267% |
| Notable Labs, Ltd. | 19.54 Million USD | -15201.53% |
| Liquidia Corporation | 120.43 Million USD | -2382.809% |
| Mustang Bio, Inc. | 17.74 Million USD | -16753.072% |
| Immunovant, Inc. | 666.71 Million USD | -348.48% |
| Quantum-Si incorporated | 298.25 Million USD | -902.539% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -1970.673% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -5420.812% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -1603.298% |
| Acasti Pharma Inc. | 73.3 Million USD | -3979.225% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -65582.94% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -11348.82% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | -209.917% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -57513.088% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -13025.289% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -5694.376% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -1554.799% |
| PepGen Inc. | 143.05 Million USD | -1990.199% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -7723.932% |
| United Therapeutics Corporation | 7.16 Billion USD | 58.28% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -15485.468% |
| Solid Biosciences Inc. | 164.93 Million USD | -1712.835% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -50818.581% |
| Immuneering Corporation | 102.58 Million USD | -2814.739% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -69297.44% |
| Silo Pharma, Inc. | 7.74 Million USD | -38500.795% |
| Belite Bio, Inc | 94.64 Million USD | -3059.35% |
| XOMA Corporation | 234.3 Million USD | -1176.167% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -1182.258% |
| Bionomics Limited | 27.64 Million USD | -10714.358% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -644.903% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2684.363% |
| uniQure N.V. | 831.68 Million USD | -259.518% |
| Cassava Sciences, Inc. | 151.66 Million USD | -1871.524% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -67029.437% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -991.725% |
| Forte Biosciences, Inc. | 38.98 Million USD | -7570.785% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -73309.976% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -8018.357% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -41290.808% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -85014.489% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -25194.577% |
| Altimmune, Inc. | 210.64 Million USD | -1319.518% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -284.387% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -2684.363% |
| Compugen Ltd. | 121.33 Million USD | -2364.332% |
| Peak Bio, Inc. | 2.59 Million USD | -115061.559% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -1635.115% |
| Benitec Biopharma Inc. | 52.21 Million USD | -5627.01% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -774.651% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -8498.832% |
| Zura Bio Limited | 100.84 Million USD | -2865.076% |
| PolyPid Ltd. | 15.37 Million USD | -19351.418% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -2406.641% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -8498.832% |
| Instil Bio, Inc. | 325.63 Million USD | -818.242% |
| argenx SE | 4.54 Billion USD | 34.175% |
| Immunome, Inc. | 148.54 Million USD | -1912.974% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -1806.022% |
| Verona Pharma plc | 308.12 Million USD | -870.412% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -3338.485% |
| Shattuck Labs, Inc. | 159.56 Million USD | -1773.901% |
| CervoMed Inc. | 9.97 Million USD | -29883.111% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -1486.615% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -26156.34% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -1566.66% |
| Moolec Science SA | 24.05 Million USD | -12332.065% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -48777.512% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -1628.921% |
| AnaptysBio, Inc. | 452.38 Million USD | -560.952% |
| Design Therapeutics, Inc. | 289.64 Million USD | -932.33% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -4005.832% |
| NeurAxis, Inc. | 509.49 Thousand USD | -586766.288% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -55087.745% |
| Lumos Pharma, Inc. | 40.63 Million USD | -7257.823% |
| Achilles Therapeutics plc | 161.45 Million USD | -1751.942% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -3338.485% |
| 180 Life Sciences Corp. | 5.25 Million USD | -56751.139% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -4145.585% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -34828.259% |
| Nutriband Inc. | 7.51 Million USD | -39676.65% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -1074.023% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -1400.279% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -3823.361% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -5062.774% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -467.872% |
| Palisade Bio, Inc. | 14.05 Million USD | -21178.622% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -1321.846% |
| Beam Therapeutics Inc. | 1.45 Billion USD | -104.84% |
| Neurogene Inc. | 222.57 Million USD | -1243.412% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -362.415% |
| AEON Biopharma, Inc. | 6.84 Million USD | -43582.571% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -560.008% |
| Sesen Bio, Inc. | 189.17 Million USD | -1480.594% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -999.829% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -21706.449% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -283.17% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -1019.902% |
| Athira Pharma, Inc. | 160.24 Million USD | -1765.938% |
| Vaccinex, Inc. | 3.63 Million USD | -82248.444% |
| HCW Biologics Inc. | 28.51 Million USD | -10386.455% |
| XOMA Corporation | 234.3 Million USD | -1176.167% |
| Nektar Therapeutics | 398.03 Million USD | -651.212% |
| Arvinas, Inc. | 1.3 Billion USD | -129.195% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -17450.118% |
| Merus N.V. | 458.49 Million USD | -552.151% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -1363.097% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -1559.271% |
| Rezolute, Inc. | 132.73 Million USD | -2152.629% |
| Clene Inc. | 52.34 Million USD | -5612.676% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -19935.489% |
| BeyondSpring Inc. | 24.8 Million USD | -11952.854% |
| Synlogic, Inc. | 75.55 Million USD | -3857.739% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -25107.149% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -31831.568% |
| Peak Bio, Inc. | 2.59 Million USD | -115061.559% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -1610.245% |
| Krystal Biotech, Inc. | 818.35 Million USD | -265.376% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -1143.594% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -311.976% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -83487.547% |
| MannKind Corporation | 475.19 Million USD | -529.227% |
| Ikena Oncology, Inc. | 192.09 Million USD | -1456.583% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -22257.35% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -2465.726% |
| Gossamer Bio, Inc. | 311.91 Million USD | -858.614% |
| CohBar, Inc. | 16.36 Million USD | -18170.395% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -8403.461% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -40775.899% |
| Legend Biotech Corporation | 1.84 Billion USD | -61.747% |
| Mural Oncology plc | 301.74 Million USD | -890.927% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -9478.959% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -52538.359% |
| Disc Medicine, Inc. | 367.99 Million USD | -712.528% |
| Champions Oncology, Inc. | 26.13 Million USD | -11342.186% |
| REGENXBIO Inc. | 573.97 Million USD | -420.946% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -110312.782% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -1836.751% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -24661.312% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -779.342% |
| Vaxart, Inc. | 91.83 Million USD | -3156.095% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -4891.449% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -1915.866% |
| Cellectis S.A. | 334.27 Million USD | -794.508% |
| Longeveron Inc. | 12.17 Million USD | -24453.063% |
| Repare Therapeutics Inc. | 253.9 Million USD | -1077.653% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 8.409% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -1388.731% |
| Revolution Medicines, Inc. | 2.08 Billion USD | -43.162% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -183904.431% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -976.685% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -1733.298% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -2055.1% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -11615.665% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 86.845% |
| Denali Therapeutics Inc. | 1.15 Billion USD | -159.124% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -24383.483% |
| Veru Inc. | 50.59 Million USD | -5809.709% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -6463.941% |
| Cingulate Inc. | 3.49 Million USD | -85540.178% |
| Passage Bio, Inc. | 150.54 Million USD | -1886.165% |
| Context Therapeutics Inc. | 16.06 Million USD | -18514.962% |
| Exicure, Inc. | 11.58 Million USD | -25721.002% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -695.13% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -1749.811% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -17013.507% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -798.608% |
| Nuvalent, Inc. | 732.38 Million USD | -308.266% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -19908.406% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -3238.848% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -20970.199% |
| OmniAb, Inc. | 401.98 Million USD | -643.827% |
| Anew Medical, Inc. | 19.45 Million USD | -15268.417% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -11087.645% |
| Lipocine Inc. | 23 Million USD | -12899.707% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -2038.714% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -878.539% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -3462.101% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -2360.155% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -37582.067% |
| Sage Therapeutics, Inc. | 882.27 Million USD | -238.904% |
| Ocugen, Inc. | 64.54 Million USD | -4532.395% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -2300.874% |
| Q32 Bio Inc. | 306.11 Million USD | -876.768% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -70956.844% |
| Alumis Inc. Common Stock | 89.61 Million USD | -3236.687% |
| Equillium, Inc. | 50.53 Million USD | -5817.419% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -3876.424% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -7144.528% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -175698.379% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -11338.246% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -4540.015% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -80124.882% |
| Dominari Holdings Inc. | 57.55 Million USD | -5094.885% |
| Edesa Biotech, Inc. | 8.89 Million USD | -33532.452% |
| vTv Therapeutics Inc. | 11.01 Million USD | -27038.065% |
| Bio-Techne Corporation | 2.81 Billion USD | -6.288% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -219.071% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -268.486% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -976.863% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -7070.093% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -347.892% |
| Nkarta, Inc. | 378.88 Million USD | -689.177% |
| BioCardia, Inc. | 2.98 Million USD | -100002.846% |
| Iterum Therapeutics plc | 26.25 Million USD | -11286.846% |